Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
This Office Action is in reply to Applicants’ correspondence of 08/17/2026.
Applicants’ remarks and amendments have been fully and carefully considered but are not found to be sufficient to put the application in condition for allowance. Any new grounds of rejection presented in this Office Action are necessitated by Applicants’ amendments. Any rejections or objections not reiterated herein have been withdrawn in light of the amendments to the claims or as discussed in this Office Action.
This Action is made FINAL.
Please Note: The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
Election/Restrictions
In the reply filed on 02/10/2023 Applicants elected, without traverse, the particular combination of genes that is TNFSF15 and ARHGAP15.
New Claim Rejections - 35 USC § 112 – Failure to Limit
Necessitated by Claim Amendments
The following is a quotation of 35 U.S.C. 112(d):
(d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph:
Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
Claim 36 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends.
Claim 36 depends from claim 1, and claim 36 recites the limitation “wherein the subject is a human.” But claim 1 is directed to a subject determined to have increased TL1A expression based in detecting, in a sample from the subject, a combination of rs6478109 and rs6757588 SNP alleles. Where the requirened SNPs are SNPs of the human genome, claim 1 is necessarily directed to the treating of a human subject, and thus claim 36 does not further limit the requirements of claim 1.
Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements.
Withdrawn Claim Rejections - 35 USC § 112 - Indefiniteness
The rejections of claims made under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as set forth on pages 2-4 of the Office Action of 05/19/2026 are withdrawn in light of the amendments to the claims.
New Claim Rejections - 35 USC § 112 – Indefiniteness
Necessitated by Claim Amendments
Claim 31 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 31 is unclear over recitation of the limitation wherein the "G" at rs6757588 comprises a "G" allele at nucleobase 501 within rs6757588”. The limitation is unclear because the nomenclature “rs6757588”, as used in the art, denotes a particular single nucleotide within the human genome context that has variable nucleotide content, it is a T>C variation in an intron of the ARHGAP15 gene on human chromosome 2. Neither the specification, the claim, nor the related art require any particular context such that a particular allelic variant (i.e.: a G as recited in the claim) is “at nucleobase 501 within rs6757588”. The specification provides that SEQ ID NO: 35 is relevant to the genomic context of the recited polymorphism, but SEQ ID NO: 35 is a 121 base sequence with variable content at position 61, and is not instructive of “nucleobase 501 within rs6757588”.
Claim Rejections - 35 USC § 112 – Written Description
Maintained in Part, Modified as Necessitated by Claim Amendments
Claims 1, 3, 25-26 and 28-36 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention.
The claims are broadly drawn to methods for a subject that is “determined to have an increased fold- change in TL1A expression based on detecting, in a sample obtained from the subject, a combination of genotypes that is associated with the increased fold-change in TL1A expression” where the genotype encompass any polymorphism in LD by an r2 of at least 0.80 with rs6478109 and rs6757588, as recited in claim 1.
The claims therefore encompass determining any of a large genus of structurally undefined genomic content (i.e.: any polymorphic single or multinucleotide insertions, deletions or substitutions, or larger structural variations, in any locus of a genome) which possess the functionality of being associated with increased TL1A expression and have the recited LD by an r2 of at least 0.80.
Relevant to the lack of particular structural limitations in the rejected claims drawn to nucleic acids, MPEP 2163 states:
The claimed invention as a whole may not be adequately described if the claims require an essential or critical feature which is not adequately described in the specification and which is not conventional in the art or known to one of ordinary skill in the art.
Additionally, at 2163IIA3(a), the MPEP states:
“…describing a composition by its function alone typically will not suffice to sufficiently describe the composition. See Eli Lilly, 119 F.3 at 1568, 43 USPQ2d at 1406 (Holding that description of a gene’s function will not enable claims to the gene “because it is only an indication of what the gene does, rather than what it is.”); see also Fiers, 984 F.2d at 1169-71, 25 USPQ2d at 1605-06 (discussing Amgen Inc. v. Chugai Pharm. Co., 927 F.2d 1200, 18 USPQ2d 1016 (Fed. Cir. 1991)). An adequate written description of a chemical invention also requires a precise definition, such as by structure, formula, chemical name, or physical properties, and not merely a wish or plan for obtaining the chemical invention claimed. See, e.g., Univ. of Rochester v. G.D. Searle & Co., 358 F.3d 916, 927, 69 USPQ2d 1886, 1894-95 (Fed. Cir. 2004) (The patent at issue claimed a method of selectively inhibiting PGHS-2 activity by administering a non-steroidal compound that selectively inhibits activity of the PGHS-2 gene product, however the patent did not disclose any compounds that can be used in the claimed methods. While there was a description of assays for screening compounds to identify those that inhibit the expression or activity of the PGHS-2 gene product, there was no disclosure of which peptides, polynucleotides, and small organic molecules selectively inhibit PGHS-2. The court held that “[w]ithout such disclosure, the claimed methods cannot be said to have been described.”).
In the case of the instant claims, the functionality of basing the conclusion that the subject has increased TL1A expression on detected genetic content is a critical feature of the claimed methods.
Relevant to the requirements of the instantly claimed methods, the specification teaches the analysis of a number of genomic variations with increased TL1A expression in IBD patients (Example 4, p.149). Relevant to the elected invention, the specification teaches that rs6478109 in the TNFSF15 gene has A and G alleles and that rs6757588 in the ARHGAP15 gene has A and G alleles, and that in samples that had a combination of a heterozygous genotype for rs6478109 and a genotype at rs6757588 that included the minor allele there was an increased TL1A fold-change ranging from 25 to 95-fold (page 152, para 0165).
However, the particular guidance of the specification does not provide the skilled artisan with the ability to predictably correlate and distinguish any other gene variant genotypes, as generically encompassed by the claims, with the required functionality of being associated with increased expression of TL1A. The specification provides guidance on general detection of variants; however, the specification does not provide guidance on how to a priori distinguish which variants have the required functionality from those that do not. Possession of the claimed invention in accordance with the requirements of 35 USC 1121(a) may not be shown by merely describing how to obtain members of the claimed genus or how to identify their common structural features. See University of Rochester, 358 F.3d at 927, 69 USPQ2d at 1895.
The gap in understanding between the specifically disclosed teachings of the application as filed and the breadth of the methods encompassed by the claims is demonstrated by the specification and the related art.
The specification teaches that when considering combinations of genotypes, while the combinations of a rs6478109 A/G and rs6757588 A/G or G/G provide increased TL1A expression, when the rs6478109 is homozygous for the risk allele there is no statistically significant level of TL1A fold-change with rs6757588.
There is further unpredictability in the scope of the claimed method when considering that the claims genotypes that are in linkage disequilibrium (LD) with other genotypes. The difficulty in identifying markers that are in linkage disequilibrium is demonstrated by the prior art of Wall et al (2003), which teaches (p.587 – Linkage disequilibrium) that patterns of LD are well known for being noisy and unpredictable. For example, pairs of sites that are tens of kilobases apart might be in ‘complete’ LD, whereas nearby pairs of sites from the same region might be in weak LD. Similarly, there can be tremendous differences in the extent of LD from one genomic region to another.
The nature of the claims in attempting to encompass genotype:phenotype association beyond those particular taught by the specification with a recitation of LD requirements is particularly relevant when considering the teachings of the related art. In this regard Sotos et al teaches that "unlike many common mathematical binary relations (e.g. equality, being greater than, divisibility), correlation is not transitive (p. 34; Sotos et al. Statistics Education Research Journal 2009, Nov. 8(2):33-55).” That is, just because A is correlated to B, and B is correlated to C, it does not necessarily follow that C is correlated to A. The only way to determine if C is correlated to A is to undertake a study and calculate the statistics to assess the relationship.
For claims drawn to a genus, as encompassed by the instant claims, the written description requirement may be satisfied through sufficient description of a representative number of species. A “representative number of species” means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. See AbbVie Deutschland GmbH & Co., KG v. Janssen Biotech, Inc., 759 F.3d 1285, 1300, 111 USPQ2d 1780, 1790 (Fed. Cir. 2014) (Claims directed to a functionally defined genus of antibodies were not supported by a disclosure that “only describe[d] one type of structurally similar antibodies” that “are not representative of the full variety or scope of the genus.”). The disclosure of only one species encompassed within a genus adequately describes a claim directed to that genus only if the disclosure “indicates that the patentee has invented species sufficient to constitute the gen[us].” See Enzo Biochem, 323 F.3d at 966, 63 USPQ2d at 1615. Further, University of California v. Eli Lilly and Co., 43 USPQ2d 1398, 1404, 1405 held that:
To fulfill the written description requirement, a patent specification must describe an invention and do so in sufficient detail that one skilled in the art can clearly conclude that “the inventor invented the claimed invention.” Lockwood v. American Airlines, Inc., 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966 (1997); In re Gosteli, 872 F.2d 1008, 1012, 10 USPQ2d 1614, 1618 (Fed. Cir. 1989) (“ [T]he description must clearly allow persons of ordinary skill in the art to recognize that [the inventor] invented what is claimed.”). Thus, an applicant complies with the written description requirement “by describing the invention, with all its claimed limitations, not that which makes it obvious,” and by using “such descriptive means as words, structures, figures, diagrams, formulas, etc., that set forth the claimed invention.” Lockwood, 107 F.3d at 1572, 41 USPQ2d at 1966.
Thus considering the breadth of the gene encompassed by the claimed methods, their specific required functionalities, and the teachings of the instant specification, it is the conclusion that the application as filed does not provide an adequate written description of the broadly claimed subject matter.
Response to Remarks
Applicants have traversed the rejection of claims made under 35 USC 112(a) as maintained above. Applicants’ arguments (p.7-8 of the Remarks of 08/17/2026) have been fully considered but are not persuasive to withdrawn the rejection. As noted in the rejection, the claims encompass any polymorphisms that are in LD by an r2 of at least 0.80 with rs6478109 and rs6757588, and further require the functionality of being associated with the increased fold-change in TL1A expression. However, neither the specification, nor the related art, allow the skilled artisan to select from the broadly encompassed genus of polymorphisms those specific polymorphism with the required traits of having an r2 of at least 0.80 with rs6478109 and rs6757588, and also are associated with the increased fold-change in TL1A expression.
Withdrawn Claim Rejections - 35 USC § 102
The rejection of claims made under 35 U.S.C. 102(a)(1) as set forth on pages 9-10 of the Office Action of 05/19/2026 is withdrawn in light of the amendments to the claims.
Conclusion
No claim is allowed.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to STEPHEN THOMAS KAPUSHOC whose telephone number is (571)272-3312. The examiner can normally be reached M-F, 8am-5pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anne Gussow can be reached at 571-272-6047. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
Stephen Kapushoc
Primary Examiner
Art Unit 1683
/STEPHEN T KAPUSHOC/Primary Examiner, Art Unit 1683